Skip to main content
. 2016 Nov 3;4(4):310–319. doi: 10.14218/JCTH.2016.00027

Table 4a. Comparison of treatment guidelines for treatment-naïve patients infected with HCV genotype 4.

AASLD/IDSA EASL WHO# APASL

  • Paritaprevir/ritonavir/ombitasvir/RBV (I-A)

  • Sofosbuvir/velpatasvir (I-A)

  • Elbasvir/grazoprevir (IIa-B)

  • Sofosbuvir/ledipasvir (IIa-B)

  • PegIFN-α/RBV/sofosbuvir (B1)

  • PegIFN-α/RBV/simeprevir, then PegIFN-α/RBV (24 weeks total) (B1)

  • Sofosbuvir/ledipasvirab (B1)

  • Paritaprevir/ritonavir/ombitasvir/RBV (A1)

  • Sofosbuvir/simepravirab (B2)

  • Sofosbuvir/daciatasvirab (B2)

  • Sofosbuvir/daclatasvirabc

  • Sofosbuvir/ledipasvirab*

Alternatives

  • Sofosbuvir/simepravirab

  • Ombitasvir/paritaprevir/ritonavir/RBVa

  • Sofosbuvir/ledispavira (A1)

  • Sofosbuvir/velpatasvir (A1)a (B1)

  • PrODa (B1)

  • Sofosbuvir/daclatasvirab (B2)
*

If the platelet count is <75 × 103/μL, then 24 weeks of treatment with RBV should be given;

#

All regimens: strong recommendation, moderate quality of evidence.

a

24 weeks in patients with cirrhosis;

b

12 weeks with RBV in patients with cirrhosis;

c

Can be used in patients with decompensated cirrhosis.

Abbreviations: PegIFN, Pegylated interferon; RBV, Ribavirin.

All treatment courses are 12 weeks unless indicated otherwise.